MLYS
Mineralys TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
MLYS vs peer average
58/100
MLYS vs. peer average (B vs. B)
Grade spread
A 1 · B 4 · C 4 · D 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ELVN is the first available peer comparator.
Enliven is another mid-cap clinical-stage biotech where valuation depends heavily on milestone timing and single-platform execution, making it a reasonable stage/risk peer despite different biology.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
MLYS
Mineralys Therapeutics
ELVN
Enliven Therapeutics
Grade
B
B
Momentum
66
73
Value
41
41
Sentiment
75
58
Setup Bias
Net Bearish
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ELVN
MLYS / ELVN
Grade Position
In line
MLYS vs. peer average (B vs. B)
58/100
Momentum
66
ELVNValue
41
MLYSSentiment
75
MLYSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs MLYS
ELVN is the first peer returned for this comparison set.